Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.52 |
| ▸ | ITGAV | P06756 | 19/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.52 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8343786 | 0.88 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL3692834 | 0.81 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL30073956 | 0.81 | ITGB3 (0.63) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6225428 | 0.81 | ITGB3 (0.63) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL8343822 | 0.79 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL8346772 | 0.78 | ITGB3 (0.50) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL11283477 | 0.76 | ADRA2A (0.61) | — | |
| SCHEMBL3686017 | 0.76 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL8542918 | 0.76 | ITGB3 (0.49) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7500489 | 0.75 | ITGB3 (0.64) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | DE CORTE BART | 2011-04-21 | — | — | US | disclosed |
| US-7879881-B2 | 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-7351711-B2 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-7351711-B2 | Tricyclic indanyls as integrin inhibitors | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
| EP-1506779-A1 | (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885ITGA2B 3/4885 |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885ITGA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.